Ramakrishna Venugopalan
CEO
Continuity Biosciences
Continuity Biosciences develops nanofluidic drug delivery systems and 3D-printed platforms for cell reprogramming and immune modulation, enabling sustained local drug release and enhanced cell engraftment. Their technologies address the challenges of effective drug delivery and cell therapy, aiming to improve treatment outcomes for chronic diseases and conditions like Type 1 diabetes and cancer.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Effective drug delivery and cell therapy face challenges in achieving sustained local drug release, targeted cell engraftment, and controlled immune modulation. Traditional methods often result in systemic side effects, limited therapeutic efficacy, and poor long-term outcomes for chronic diseases and conditions.
Solution
Continuity Biosciences develops and licenses technology platforms focused on advanced drug delivery and cell therapy. Their portfolio includes nanofluidic drug delivery systems and 3D-printed platforms designed for cell reprogramming and immune modulation. These technologies enable sustained, localized drug release, enhanced cell engraftment, and precise control over the immune response. By exploiting nanoscale physics, Continuity Biosciences aims to improve treatment outcomes for diseases like Type 1 diabetes, cancer, and HIV, while minimizing systemic side effects and enhancing medication adherence. The company's technology-agnostic and patient-centric approach allows them to offer multiple solutions for achieving desired product presentation strategies.
Target Audience
Continuity Biosciences targets biopharmaceutical companies, research institutions, and medical technology firms seeking advanced drug delivery and cell therapy solutions to improve treatment outcomes for chronic diseases.
Features
- Neovascularized Implantable Cell Homing and Encapsulation (NICHE) platform: A 3D-printed implant that creates a vascularized microenvironment for long-term cell engraftment and local immune modulation, suitable for pancreatic beta cell therapy in T1D.
- NanoLymph platform: A 3D-printed platform with dual reservoirs for in vivo cell recruitment and reprogramming, coupled with immunomodulatory agent release for cancer vaccination and immune modulation therapies.
- Nanofluidic drug-eluting seed (NDES): A small implant featuring a silicon nanofluidic membrane for sustained local drug delivery within solid tumors, enabling localized chemotherapy and immunotherapy.
- Nanochannel drug delivery system (nDS): A refillable, long-term subcutaneous implant based on tunable silicon membrane technology, providing continuous, sustained release of therapeutics for chronic disease treatment and prevention, such as HIV PrEP.
- Tunable silicon membrane technology allows for precise control over drug release kinetics.
- 3D-printed platforms enable customized designs for specific therapeutic applications.